FIELD: medicine.
SUBSTANCE: group of inventions relates to a fixed combination and its use for the reduction in LDL-C containing ETC-1002 and one or more statins selected from a group consisting of atorvastatin, rosuvastatin and simvastatin, wherein the amount of ETC-1002 is 180 mg, the amount of atorvastatin is 40-80 mg, the amount of rosuvastatin is 20-40 mg, and the amount of simvastatin is 40-80 mg.
EFFECT: group of inventions provides a lower or equal frequency of undesirable events occurring during the treatment from the musculoskeletal system and connective tissue, compared with the administration of a fixed dose of one or more statins.
21 cl, 2 dwg, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FIXED COMBINATIONS AND COMPOUNDS CONTAINING ETC-1002 AND EZETIMIBE, AND METHOD FOR TREATING OR REDUCING THE RISK OF DEVELOPING A CARDIOVASCULAR DISEASE | 2016 |
|
RU2766085C2 |
| METHODS OF TREATING PATIENTS WITH A HIGH RISK OF CARDIOVASCULAR DISEASES HAVING HYPERCHOLESTEROLEMIA | 2015 |
|
RU2723018C2 |
| HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS | 2012 |
|
RU2603481C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIBODIES TO HUMAN PCSK9 | 2012 |
|
RU2604139C2 |
| TREATING WITH ANTI-PCSK9 ANTIBODIES | 2012 |
|
RU2576034C2 |
| METHODS OF TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) | 2015 |
|
RU2735521C2 |
| PHARMACEUTICAL COMPOSITION FOR HYPERLIPIDEMIA TREATMENT | 2014 |
|
RU2623876C2 |
| PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HYPERLIPIDEMIA | 2017 |
|
RU2683641C2 |
| 1-METHYLNIKOTINAMIDE USE FOR TREATMENT OF DISEASES ASSOCIATED WITH C-REACTIVE PROTEIN | 2017 |
|
RU2744615C2 |
| METHODS FOR TREATMENT OF HYPERLIPIDEMIA IN PATIENTS WITH DIABETES BY INJECTION OF PCSK9 INHIBITOR | 2018 |
|
RU2772712C2 |
